Expression and prognostic significance of cathepsin L in early cutaneous malignant melanoma

Neoplasma

Volumn 53, Issue 3, 2006, Pages 259-262

  Stabuc B ^a   Mrevlje, Z ^a   Markovic J ^a   Stabuc Silih M ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Cathepsin L; Malignant melanoma; Prognosis; Tumor marker

Indexed keywords

CATHEPSIN L; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PROGNOSIS; PROTEIN EXPRESSION; SKIN TUMOR; ULCER;

EID: 33744931947     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. DUFFY MJ. Proteasesas prognostic markers in cancer. Clin Cancer Res 1996; 2: 613-618.
2. LIOTTA LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial award lecture. Cancer Res 1986; 46(1): 1-7.
3. CHAUHAN SS, GOLDSTEIN LJ, GOTTESMAN MM. Expression of Cathepsin L in human tumors. Cancer Res 1991; 51: 1478-1481.
4. TURK B, TURK D, TURK V. Lysosomal cysteine proteases: more than scavengers. Biochem Biophys Acta 2000; 1477: 98-111.
5. DAHL SW, HALKIER T, LAURITZEN C, DOLENC I, PEDERSEN J et al. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. Biochemistry 2001; 40: 1671-1678.
6. ROTH W, DEUSSING J, BOTCHKAREV VA, PAULY-EVERS M, SAFTIG P et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J 2000; 14: 2075-2086.
7. FELBOR U, DREIER L, BRYANT RA, PLOEGH HL, OLSEN BR et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19(6): 1187-1194.
8. LETO G, TUMMINELLO FM, PIZZOLANTI G, MONTALTO G, SORESI M et al. Lysosomal Cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology 1997; 54: 79-83.
9. THOMSSEN C, SCHMITT M, GORETZKI L, OPPELT P, PACHE L et al. Prognostic value of the cysteine proteases Cathepsin B and Cathepsin L in human breast cancer. Clin Cancer Res 1995; 1: 741-746.
10. STROJAN P, BUDIHNA M, ŠMID L, SVETIC B, VRHOVEC I et al. Cathepsin B and L and Stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma 2001; 48(1): 66-71.
11. CAMPO E, MUNOZ J, MIQUEL R, PALACIN A, CARDESA A et al. Cathepsin B expression in colorectal carcinomas correkates with tumor progression and shortened patient survival. Am J Pathol 1994; 145(2): 301-309.
12. SUKOH N, ABE S, OGURA S, ISOBE H, TAKEKAWA H et al. Immunohistochemical study of Cathepsin B. Prognostic significance in human lung cancer. Cancer 1994; 74(1): 46-51.
13. FROEHLICH E, SCHLAGENHAUFF B, MOEHRLE M, WEBER E, KLESSEN C et al. Activity, expression, and transcription rate of the Cathepsins B, D, H and L in cutaneous malignant melanoma. Am Cancer Soc 2001; 91(5): 972-982.
14. KAGESHITA T, YOSHII A, KIMURA T, MARUO K, ONO T et al. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. Arch Dermatol Res 1995; 287(3-4): 266-272.
15. FRADE R, RODRIGUES-LIMA F, HUANG S, XIE K, GUILLAUME N, et al. Procathepsin L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res 1998; 58: 2733-2736.
16. BALCH CM, BUZAID AC, SOONG SJ. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19: 3635-3548.
17. KOS J, ŠTABUC B, SCHWEIGER A. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 1997; 3: 1815-1822.
18. KANE SE, GOTTESMAN MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol 1990; 1: 127-136.
19. TROY AM, SHEAHAN K, MULCHANY HE, DUFFY MJ, HYLAND JMP et al. Expression of Cathepsin Band L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer 2004; 40: 1610-1616.
20. MURNANE M, SHUJA S, DEL RE E, CAI J, IACOBUZIO-DONAHUE C et al. Characterizing human colorectal carcinomas by proteolytic profile. In Vivo 1997; 11: 209-216.
21. KIRSCHKE H, EEROLAR, HOPSU VK, HAVU VK, BROEMME D et al. Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer 2001; 36(6): 787-795.
22. SEVER N, FILIPIC M, BRZIN J, LAH T. Effect of cysteine proteinase inhibitors on Murine B16 melanoma cell invasion in vitro. Biol Chemistry 2002; 383(5): 839-842.
23. ERVIN H, COX JL. Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell Int 2005; 5: 14-21.
24. SLOMINSKI A, ROSS J, MIHM MC. Cutaneous melanoma: pathology, relevant prognostic indicators and progression. Br Med Bull 1995; 51: 548-569.
25. FOEKENS JA, KOS J, PETERS HA, KRAŠOVEC M, LOOK MP et al. Prognostic significance of Cathepsins B and L in primary human breast cancer. J Clin Oncol 1998; 16(3): 1013-1021.
26. BUDIHNA M, STROJAN P, ŠMID L, ŠKRK J, VRHOVEC I et al. Prognostic value of cathepsinc B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem 1996; 377: 385-390.